| Name | Title | Contact Details |
|---|
Essex Group Management is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rippl is a new kind of mental health company focused on seniors and obsessed with its clinicians. Seniors with mental health challenges, especially neurocognitive conditions like Alzheimer`s disease and other dementias, are overlooked and under cared for, often without access to high quality, real-time, practical care.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Nutrition isn`t complicated. For us, it`s natural. We`ve been a leader in the research and development of carotenoid-based products for the last two decades and we take that role very seriously. This means we approach everything we do with a sense of wonder and a driving desire to find the best possible outcome or create the highest-quality product.
Integrity Medicolegal Ents is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.